You are here

Canada House Wellness Group Announces Filing of First Quarter Financial Statements and Related Documents and provides Update on Status of Management Cease Trade Order


TORONTO, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) is pleased to announce that it has filed its interim unaudited financial statements for the quarter ended July 31, 2017 and related management’s discussion and analysis and Chief Executive Officer and Chief Financial Officer certificates. With the filing of such documents, the Company has effected all filings it is required to make under Ontario securities law. Accordingly,  the management cease trade order (“MCTO”) issued by the Ontario Securities Commission in respect of the Company’s securities under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults (“NP 12-203”) will be lifted following two full business days, being the end of trading on November 22, 2017.

The MCTO was initially issued in respect of the Company’s inability to file its audited financial statements for the year ended April 30, 2017 and the management’s discussion and analysis and related Chief Executive Officer and Chief Financial Officer certificates for such period before the August 28, 2017 filing deadline. The Company effected those filings on October 30, 2017 but was, at that time, in default of filing its interim unaudited financial statements for the quarter ended July 31, 2017 and related management’s discussion and analysis and Chief Executive Officer and Chief Financial Officer certificates as required to have been filed on or before September 29, 2017 All filings required by the Company under Ontario securities law are now up to date.

Canada House Wellness Group Inc.

Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company's goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit or

Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information, please contact:
Boom Capital Markets
Steve Low

Canada House Wellness Group, Inc.
Gerry Goldberg
(416) 460-3000 
Monday, November 20, 2017 - 16:30

More Headlines

Zulresso May Alleviate Symptoms for Thousands of Women
Developed for Tumors Resistant to Other TKIs
New Drug Reduces Infection in Chemotherapy Patients
Daily Use of AHCC Supplement Could Support Immune System, Eliminate HPV
Unique Bio-Identical Hormone Therapy for Treatment of Hot Flashes
High-Tech “Nightwatch” is Capable of Detecting 85 Percent of Severe Night-Time Epileptic Seizures
Combination of Buprenorphine and Samidorphan Targets Opioid System Safely and Effectively
Prevents Harmful Effects of Chemotherapy